W
Weily Soong
Researcher at University of Alabama at Birmingham
Publications - 59
Citations - 1148
Weily Soong is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 21 publications receiving 646 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Diamant Thaçi,Eric L. Simpson,Lisa A. Beck,Thomas Bieber,Andrew Blauvelt,Kim A. Papp,Weily Soong,Margitta Worm,Jacek C Szepietowski,Howard Sofen,M. Kawashima,Richard Wu,Steven P. Weinstein,Neil M.H. Graham,Gianluca Pirozzi,Ariel Teper,E. Rand Sutherland,Vera Mastey,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +20 more
TL;DR: Dupilumab improved clinical responses in adults with moderate-to-severe atopic dermatitis in a dose-dependent manner, without significant safety concerns, and shows that IL-4 and IL-13 are key drivers of atopic skinitis.
Journal ArticleDOI
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Kristian Reich,Henrique D. Teixeira,Marjolein S. de Bruin-Weller,Thomas Bieber,Weily Soong,Kenji Kabashima,Thomas Werfel,Jiewei Zeng,Xiaohong Huang,Xiaofei Hu,Barbara A. Hendrickson,Barry Ladizinski,Alvina D. Chu,Jonathan I. Silverberg +13 more
TL;DR: In this paper, upadacitinib plus topical corticosteroids compared with placebo for the treatment of moderate-to-severe atopic dermatitis was evaluated in a randomized, double-blind, placebo-controlled, phase 3 trial.
Journal ArticleDOI
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
Eric L. Simpson,Abhijit Gadkari,Margitta Worm,Weily Soong,Andrew Blauvelt,Laurent Eckert,Richard Wu,Marius Ardeleanu,Neil M.H. Graham,Gianluca Pirozzi,E. Rand Sutherland,Vera Mastey +11 more
TL;DR: In this article, dupilumab treatment was evaluated on patient-reported outcomes in adults with moderate to severe atopic dermatitis (AD) and the two 300-mg dose regimens resulted in the greatest benefits.
Journal ArticleDOI
Dupilumab Shows Long-Term Safety and Efficacy in Patients With Moderate to Severe Atopic Dermatitis Enrolled in a Phase 3 Open-Label Extension Study
Mette Deleuran,Diamant Thaçi,Lisa A. Beck,Marjolein S. de Bruin-Weller,Andrew Blauvelt,Seth Forman,Robert Bissonnette,Kristian Reich,Weily Soong,Iftikhar Hussain,Peter Foley,Michihiro Hide,Jean-David Bouaziz,Joel M. Gelfand,Lawrence Sher,Marie L A Schuttelaar,Chen Wang,Zhen Chen,Bolanle Akinlade,Abhijit Gadkari,Laurent Eckert,John D. Davis,Manoj Rajadhyaksha,Heribert Staudinger,Neil M.H. Graham,Gianluca Pirozzi,Marius Ardeleanu +26 more
TL;DR: The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate-to-severe atopic dermatitis.
Journal ArticleDOI
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
Jonathan I. Silverberg,Ingrid Maria,Marjolein S. de Bruin-Weller,Thomas Bieber,Weily Soong,Kenji Kabashima,Antonio Costanzo,David Rosmarin,Charles Lynde,J. Liu,Amy Gamelli,Jiewei Zeng,Barry Ladizinski,Alvina D. Chu,Kristian Reich +14 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of upadacitinib+ topical corticosteroid (TCS) in patients with moderate-to-severe atopic dermatitis through 52 weeks.